Coronavirus Vaccine Trial Adverse Event Was Probably Unrelated to Treatment

After reviewing the adverse event that caused AstraZeneca (NYSE: AZN) to pause the clinical trials of its coronavirus vaccine, AZD1222, an independent review determined there's nothing to worry about. "After independent review, these illnesses were either considered unlikely to be associated with the vaccine or there was insufficient evidence to say for certain that the illnesses were or were not related to the vaccine," the clinical trial organizers for the phase 2/3 U.K. clinical trial wrote in the participant-information sheet, which was updated on Friday. The volunteers developed "unexplained neurological symptoms including changed sensation or limb weakness," which is a little more descriptive than simply calling it an "unexplained illness," as AstraZeneca did when it acknowledged that the clinical trials had been paused last week.